XBIT Jul 2024 5.000 call
| Previous Close | 4.0300 |
| Open | 4.0300 |
| Bid | 1.0000 |
| Ask | 5.6000 |
| Strike | 5.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 4.0300 - 4.0300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 13 |
GlobeNewswireXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen
Simply Wall St.XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by...
GlobeNewswireXBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou
